Entering text into the input field will update the search result below

Gilead’s COVID-19 therapy beats AbbVie’s Humira to lead U.S. hospital spending in 2021

Remdesivir vials antiviral drug

humonia/iStock via Getty Images

Gilead’s (NASDAQ:GILD) COVID-19 therapy remdesivir has claimed the top spot, overtaking AbbVie’s (NYSE:ABBV) anti-inflammatory medication Humira in a list of drugs compiled by the purchasing group Vizient Inc, based on the spending of its member hospitals.

From

Recommended For You

Related Stocks

SymbolLast Price% Chg
GILD--
Gilead Sciences, Inc.
ABBV--
AbbVie Inc.
MRK--
Merck & Co., Inc.
RHHBY--
Roche Holding AG